Currently, a phase I clinical trial (NCT02658981) is assessing the safety and dosage of anti-LAG-3 monoclonal antibody BMS-986016 alone or in combination with nivolumab to overcome PD-1 resistance in recurrent GBM. Here, PDCD1 is linked to glioblastoma.